H-02 — Transcendental Meditation and High Blood Pressure

Evidence status: A — Strong/current

The evidence considered here is drawn from randomized controlled trials, systematic reviews and meta-analyses of Transcendental Meditation (TM) and blood pressure, together with the 2025 American Heart Association/American College of Cardiology (AHA/ACC) Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults.

Key evidence includes:

Anderson JW, Liu C, Kryscio RJ. Blood pressure response to Transcendental Meditation: a meta-analysis. American Journal of Hypertension. 2008;21(3):310–316. DOI: 10.1038/ajh.2007.65.

Bai Z, Chang J, Chen C, Li P, Yang K, Chi I. Investigating the effect of Transcendental Meditation on blood pressure: a systematic review and meta-analysis. Journal of Human Hypertension. 2015;29(11):653–662. DOI: 10.1038/jhh.2015.6.

Schneider JK, Reangsing C, Willis DG. Effects of Transcendental Meditation on Blood Pressure: A Meta-analysis. Journal of Cardiovascular Nursing. 2022;37(3):E11–E21. DOI: 10.1097/JCN.0000000000000849.

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults.

Does regular practice of Transcendental Meditation produce a clinically meaningful reduction in blood pressure in adults with or without hypertension?

Successive reviews have produced remarkably consistent findings in direction, although the estimated size of the effect varies.

The 2008 meta-analysis found that TM, compared with control conditions, was associated with average reductions of:

4.7 mmHg systolic
3.2 mmHg diastolic

Similar reductions were found when the analysis was restricted to people with hypertension and to higher-quality studies.

The 2015 independent meta-analysis, involving 996 participants, found average reductions of:

4.26 mmHg systolic
2.33 mmHg diastolic

The 2022 meta-analysis, involving 1,207 participants, found somewhat smaller average reductions of:

3.3 mmHg systolic
1.8 mmHg diastolic

That analysis also found that the measured effects tended to diminish after three months, while older participants appeared to experience larger reductions in systolic blood pressure.

Taken together, the randomized-trial evidence indicates that regular TM practice can produce a modest reduction in blood pressure, commonly averaging approximately 3–5 mmHg systolic and around 2–3 mmHg diastolic, although the magnitude varies between studies and over time.

The 2025 AHA/ACC blood-pressure guideline provides an important contemporary assessment of this evidence.

The guideline states that there is “consistent moderate- to high-level evidence” from short-term clinical trials that TM can lower blood pressure in people both with and without hypertension. It describes mean reductions of approximately 5 mmHg systolic and 2 mmHg diastolic.

Its lifestyle-intervention table identifies TM specifically and describes the intervention as training by a professional followed by two 20-minute sessions each day while seated comfortably with the eyes closed.

The table estimates an approximate systolic blood-pressure reduction of 5–7 mmHg in people with hypertension and approximately 5 mmHg in those without hypertension.

The guideline also distinguishes TM from the broader group of stress-reduction and mindfulness interventions, for which it describes the evidence as less robust and of lower quality.

Evidence strength and clinical recommendation are not the same thing

An important distinction needs to be made.

Although the 2025 guideline describes the short-term clinical-trial evidence for TM as consistent and moderate to high level, its formal clinical recommendation remains cautious.

For adults with or without hypertension, it states that stress reduction through TM “may be reasonable” for preventing or treating elevated blood pressure and hypertension as an adjunct to lifestyle or medication interventions.

This recommendation is classified:

Class of Recommendation: 2b
Level of Evidence: B-R (randomized evidence)

The 2025 guideline therefore does not say that TM should replace medication or established lifestyle interventions.

Rather, two conclusions coexist:

1. The accumulated short-term evidence that TM lowers blood pressure is now assessed as reasonably consistent and of moderate-to-high quality.

1. The formal clinical recommendation remains cautious — TM may be reasonable as an adjunct to established lifestyle measures or medication.

This distinction is important when comparing the current position with earlier AHA statements.

A reduction of several mmHg may appear numerically small, but modest reductions in blood pressure can be clinically relevant, particularly when maintained over time and across populations.

TM may therefore provide a useful additional non-pharmacological approach for people with elevated blood pressure or hypertension, particularly where stress is also an issue.

The 2025 guideline nevertheless indicates that meditation appears somewhat less effective for blood-pressure reduction than leading lifestyle interventions such as the DASH eating plan, structured exercise, and reduced sodium/increased potassium intake.

TM should therefore be regarded as an adjunct, rather than an alternative, to appropriate medical care and established lifestyle measures.

People taking antihypertensive medication should not reduce or discontinue medication without medical advice.

TM is a non-pharmacological behavioural intervention and does not carry the medication adverse-effect profile associated with antihypertensive drugs.

However, the blood-pressure literature does not establish that every individual will respond, nor does it justify replacing prescribed treatment.

Long-term adherence should also be kept separate from the principal blood-pressure claim. Although TM is intended as a continuing twice-daily practice, much of the clinical-trial evidence is comparatively short term. Strong claims about long-term adherence or continuity of blood-pressure reduction therefore require their own evidence.

A scientifically defensible summary of the evidence is:

Randomized controlled trials and independent meta-analyses indicate that regular practice of Transcendental Meditation can produce modest but clinically relevant reductions in blood pressure. The 2025 AHA/ACC hypertension guideline describes the short-term clinical-trial evidence for TM as consistent and moderate to high level, with mean reductions of approximately 5 mmHg systolic and 2 mmHg diastolic. Its formal recommendation remains cautious: TM may be reasonable as an adjunct to established lifestyle measures or medication for adults with or without hypertension.

Strengths: randomized controlled evidence; objective blood-pressure measurement; repeated meta-analysis; independent systematic assessment; consistent direction of effect; recognition in the 2025 AHA/ACC guideline.

Limitations: generally small and relatively short trials; heterogeneity between study designs and populations; variable study quality; uncertainty about the persistence of the effect over longer periods.